Ketamine effectively treats depression, but recent studies illustrate the ongoing difficulties in understanding its antidepressant effects at a molecular level.
By masking ketamine from placebo for the first time, researchers reveal the importance of accounting for expectancy in trials testing psychoactive drugs.